Atazanavir is metabolized in the liver with the cytochrome system; it is also an inhibitor of isozyme , included in the system.
The combined use of the drug Reyataz and other drugs with the same metabolic pathways (blockers “slow” calcium channel inhibitors, hydrate-H-3-methylglutaryl-coenzyme A reductase, immunosuppressants fosfodizsterazy inhibitors) may lead to an increase in the concentration of one of them in the plasma, which may lead to increased severity or prolonging its therapeutic and side effects.
The combined use of the drug Reyataz and drugs that induce may result to a significant drop in plasma concentration of atazanavir and thereby reducing its therapeutic activity.The combined use of the drug Reyataz and drugs that inhibit , can lead to an increase in the concentration of atazanavir. plasma Intensity proviron dosageinteractions of atazanavir with other medications (change atazanavir effects or change the effect of another drug) can be changed while taking the drug Reyataz with ritonavir, a potent inhibitor .
For completeness of information on drug interactions with ritonavir should be familiar with the instructions for use of ritonavir .
Drugs that should not be used in conjunction with drug Reyataz :Hinidnn: application, together with a combination of Reyataz / ritonavir is contraindicated due to the risk of serious and life-threatening arrhythmias. rifampicin: in the combined use of atazanavir with rifampicin substantially decreases atazanavir plasma concentration, leading .k reduce the therapeutic efficacy and the development of drug resistance to Reyataz. Concomitant use of atazanavir and rifampicin is contraindicated. Irinotecan: atazanavir inhibits UDP-glucuronosyltransferase (UGT) and may affect the metabolism of irinotecan, causing an increase of its toxicity, so concomitant proviron dosage use with atazanavir with irinotecan is contraindicated. Bepridil: due to the high risk of life-threatening side the effects of the combined use with the drug Reyataz is contraindicated. The derivatives of ergotamine (dihydroergotamine, ergotamine, ergometrine, metilergometrin): due to the high risk of life-threatening side effects of the combined use with the drug Reyataz is contraindicated.Manifestations of acute toxicity derivatives of ergotamine: peripheral vasospasm, ischemia of the extremities and other areas. Cisapride: due to the high risk of life-threatening side effects (arrhythmia), the combined use with the drug Reyataz is contraindicated. HMG-CoA reductase inhibitors (lovastatin, simvastatin): increased the risk of myopathy, including rhabdomyolysis. pimozide:. due to the high risk of life-threatening side effects (arrhythmia), the combined use with the drug Reyataz is contraindicated indinavir: the combined use with the drug Reyataz is not recommended, since both drugs can cause hyperbilirubinemia. Midazolam, triazolam : concomitant use with the drug Reyataz is contraindicated due to the possibility of increasing the concentration of midazolam / triazolam and high risk of extending sedatpvnogo effects and respiratory depression. Drugs St. John’s wort (Hypericum perforatum): combination with the drug Reyataz is contraindicated, since the concentration of atazanavir in plasma may be reduced, resulting in . in the loss of therapeutic effect and development of resistance to the following medicines may need to change dosage regimen in connection with the expected interactions: Antiretroviral treatment for HIV Nukleozndnye proviron dosage reverse transcriptase inhibitors: didanosine: contained in tablets of ddI buffer components increase the acidity of gastric juice, so when used together with didanosine tablets effect of atazanavir markedly reduced. Reyataz does not affect the efficiency of ddI in a joint application. Application of enteric-coated didanosine tablets with drug Reyataz PLI with Reyataz preparations and / or ritonavir and with food reduces the availability of didanosine.